Łopuszyńska Natalia, Węglarz Władysław P
Department of Magnetic Resonance Imaging, Institute of Nuclear Physics Polish Academy of Sciences, 31-342 Cracow, Poland.
Nanomaterials (Basel). 2023 Jul 25;13(15):2163. doi: 10.3390/nano13152163.
Poor pharmacokinetics and low aqueous solubility combined with rapid clearance from the circulation of drugs result in their limited effectiveness and generally high therapeutic doses. The use of nanocarriers for drug delivery can prevent the rapid degradation of the drug, leading to its increased half-life. It can also improve the solubility and stability of drugs, advance their distribution and targeting, ensure a sustained release, and reduce drug resistance by delivering multiple therapeutic agents simultaneously. Furthermore, nanotechnology enables the combination of therapeutics with biomedical imaging agents and other treatment modalities to overcome the challenges of disease diagnosis and therapy. Such an approach is referred to as "theranostics" and aims to offer a more patient-specific approach through the observation of the distribution of contrast agents that are linked to therapeutics. The purpose of this paper is to present the recent scientific reports on polymeric nanocarriers for MRI-guided drug delivery. Polymeric nanocarriers are a very broad and versatile group of materials for drug delivery, providing high loading capacities, improved pharmacokinetics, and biocompatibility. The main focus was on the contrasting properties of proposed polymeric nanocarriers, which can be categorized into three main groups: polymeric nanocarriers (1) with relaxation-type contrast agents, (2) with chemical exchange saturation transfer (CEST) properties, and (3) with direct detection contrast agents based on fluorinated compounds. The importance of this aspect tends to be downplayed, despite its being essential for the successful design of applicable theranostic nanocarriers for image-guided drug delivery. If available, cytotoxicity and therapeutic effects were also summarized.
药物的药代动力学不佳、水溶性低以及从循环系统中快速清除,导致其疗效有限且治疗剂量通常较高。使用纳米载体进行药物递送可以防止药物快速降解,从而延长其半衰期。它还可以提高药物的溶解度和稳定性,促进药物的分布和靶向性,确保药物持续释放,并通过同时递送多种治疗剂来降低耐药性。此外,纳米技术能够将治疗剂与生物医学成像剂及其他治疗方式相结合,以克服疾病诊断和治疗的挑战。这种方法被称为“治疗诊断学”,旨在通过观察与治疗剂相连的造影剂的分布,提供一种更针对患者的方法。本文的目的是介绍有关用于磁共振成像(MRI)引导药物递送的聚合物纳米载体的最新科学报告。聚合物纳米载体是一类非常广泛且用途多样的药物递送材料,具有高载药量、改善的药代动力学和生物相容性。主要重点在于所提出的聚合物纳米载体的对比特性,可将其分为三大类:(1)带有弛豫型造影剂的聚合物纳米载体,(2)具有化学交换饱和转移(CEST)特性的聚合物纳米载体,以及(3)基于氟化化合物的直接检测造影剂的聚合物纳米载体。尽管这一方面对于成功设计适用于图像引导药物递送的治疗诊断纳米载体至关重要,但它的重要性往往被低估。如有相关信息,还总结了细胞毒性和治疗效果。